Thanks very much, this answers the question about whether the trial is blinded, or not, it's both. The company should be able to tell us the result of the first part of the trial, and they'll only do the second part of the trial if they see efficacy in the first.
What's not shown at this point is an approach at other skin diseases. I suspect that if they see efficacy in psoriasis, then they'll look at other skin diseases.
Now if we could only learn the status of these trials. If they put them in the clinical trials database we'd know.
I was of the belief that they also had Israeli hospitals working with them on the trial, am I wrong about that. I believe the initial safety trial for the cream was done in a hospital.
Gary